NCT01813253 - Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer | Biotech Hunter

Enrollment

400

Participants

Timeline

Start Date

May 13, 2013

Primary Completion Date

February 19, 2018

Study Completion Date

February 19, 2018

Conditions

Gastric CancerGastroesophageal Junction Cancer

Interventions

DRUG

Irinotecan

150 mg/m2 IV once every 2 weeks until progression or unacceptable toxicity develops

DRUG

Nimotuzumab

400mg IV once weekly until progression or unacceptable toxicity develops

Trial Locations (37)

277-0882

National Cancer Center Hospital East, Kashiwa

Unknown

Aichi

Akita

Aomori

Ehime

Fukuoka

Hiroshima

Hokkaido

Hyōgo

Kanagawa

Kumamoto

Kyoto

Nagano

Niigata

Osaka

Saitama

Shizuoka

Tochigi

Tokyo

Toyama

Busan

Daegu

Hwansun Junnam hospital, Gwangju

Gyeonggi-do

Incheon

Jeonju

Seongnam

Seoul

Yangsan

Changhua

Tainan City

Taipei

Taoyuan District

Thaichung

206-8717

Chiba

920-8530

Ishikawa

420-8527

Shizuoka